Interpace Q1 revenue up 6% to $10.4M; net loss narrows to $2.2M from $4.2M

INTERPACE BIOSCIENCES, INC.

2023-Q1 EPS reported -$0.53 revenue$2,454,000

Q1 revenue $10.4M, +6% YoY; net loss improved to $2.2M from $4.2M in Q1 2021.
Gross margin 48% vs 46% prior year; DSO decreased 27% to 63 days.
Adjusted EBITDA loss $0.9M, flat YoY; cash $2.9M at March 31, 2022.
Entered $2M convertible note agreement with BroadOak Fund V, L.P. on May 5, 2022 for working capital.
Collaboration with Twist Bioscience and Miroculus to automate NGS library prep using digital microfluidics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.